Despite FDA Setback, MEI’s Zandelisib Could Still Break PI3K Curse

Drug Faces Longer Path To Market

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

MEI/Kyowa Kirin will no longer seek accelerated approval based on a single-arm study as the FDA is calling for Phase III data due to growing conservatism regarding the PI3K class.

MEI and Kyowa Kirin face a delay due to the FDA's more conservative stance on PI3K inhibitors • Source: Alamy

MEI Pharma, Inc.’s PI3K inhibitor zandelisib faces a longer road to the market than the company anticipated as the US Food and Drug Administration has adopted a more cautious stance on the long-troubled class and discouraged the company from filing for accelerated approval based on Phase II data. But given the zandelisib’s favorable toxicity profile relative to its peers, that longer road does not mean it is doomed, though it will have to meet a high efficacy bar to be competitive.

MEI and partner Kyowa Kirin Co., Ltd. said on 24 March that they would not seek accelerated approval for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.